Clinical Trial Update: Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations [Phase 1, Phase 2]

View source ↗

Summary

This is a completed Phase 1/2 clinical trial investigating WNT974 in combination with LGX818 and cetuximab in patients with BRAF-mutant metastatic colorectal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• LGX818 (encorafenib)
• WNT974

Snippet

Sponsor: Array BioPharma | Conditions: Metastatic Colorectal Cancer | Phase 1, Phase 2 | Status: COMPLETED